What are the next-generation sequencing methods in precision oncology?
NGS is a highly scalable technology—the spectrum of analysis can extend from a small number of genes to an entire genome, depending upon the goal.
Whole-genome sequencing (WGS) and whole-exome sequencing (WES) identify every DNA base across the genome and exome, respectively. Yielding massive data sets, these methods are ideal for research and discovery efforts.
Whole-transcriptome sequencing identifies coding and noncoding RNA to assess variations and gene expression levels across the entire transcriptome. This method is also better suited for research and discovery efforts.
While the value of WGS and WES has been recognized in studying oncology, these methods are impractical in the clinical arena due to costs, long turn-around time to results (weeks), and the complexities of data storage, analysis, and interpretation.
Targeted sequencing panels profile a small set of genes that are curated for a specific application or disease. Featuring actionable biomarkers, these panels are commonly used in clinical applications as they help inform the diagnosis, treatment, and monitoring of individual patient disease.
Learn More